INTECH Investment Management’s Aquestive Therapeutics AQST Stock Holding History

INTECH Investment Management’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$166K	Buy	39,869 +14,151	+55%	+$59.5K	﹤0.01%	1836
2026 Q1	$107K	Sell	25,718 -8,195	-24%	-$33.3K	﹤0.01%	1882
2025 Q4	$219K	Buy	33,913 +12,566	+59%	+$78.3K	﹤0.01%	1934
2025 Q3	$119K	Sell	21,347 -33,046	-61%	-$143K	﹤0.01%	2216
2025 Q2	$180K	Buy	54,393 +12,600	+30%	+$36.1K	﹤0.01%	2127
2025 Q1	$121K	Buy	41,793 +2,116	+5%	+$6.41K	﹤0.01%	2262
2024 Q4	$141K	Buy	39,677 +21,645	+120%	+$99.8K	﹤0.01%	2134
2024 Q3	$89.8K	Buy	+18,032	New	+$70.2K	﹤0.01%	1902

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

INTECH Investment Management's AQST Position: Q2 2026 in Review

INTECH Investment Management increased its Aquestive Therapeutics (AQST) stake by 55% in Q2 2026, buying an estimated $59.5K and bringing the position to 39,869 shares worth $166K. The position accounts for ﹤0.01% of the portfolio, ranked #1836.

INTECH Investment Management first reported a position in AQST in Q3 2024 and has held it in 8 quarters since. The position peaked at $219K in Q4 2025. 184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

INTECH Investment Management held 39,869 shares of Aquestive Therapeutics worth $166K as of Q2 2026.
INTECH Investment Management bought 14,151 Aquestive Therapeutics shares in Q2 2026, an estimated $59.5K.
Aquestive Therapeutics made up ﹤0.01% of INTECH Investment Management's portfolio in Q2 2026, its #1836 holding.
INTECH Investment Management first reported a position in Aquestive Therapeutics in Q3 2024 and has held it in 8 quarters since.
INTECH Investment Management's Aquestive Therapeutics position peaked at $219K in Q4 2025.
184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on INTECH Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.